search
Back to results

Hypoxic-Ischemic Encephalopathy Therapy Optimization in Neonates for Better Neuroprotection With Inhalative CO2 (HENRIC)

Primary Purpose

Hypoxic-Ischaemic Encephalopathy, Perinatal Asphyxia, Hypocapnia

Status
Completed
Phase
Phase 1
Locations
Hungary
Study Type
Interventional
Intervention
5% carbon-dioxide inhalation
Sponsored by
Semmelweis University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypoxic-Ischaemic Encephalopathy focused on measuring Hypothermia treatment, Hypocapnia, Inhaled CO2, Neuroprotection

Eligibility Criteria

undefined - 6 Hours (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • At any time within six hours of life the temperature corrected pCO2 is less than or equal to 40 mmHg after the parameters of mechanical ventilation is set according to standard protocol (SIMV+VG 5ml/kg, fr 20/min, PEEP 5 H20cm, Ti 0,35-0,45 sec).
  • Moderate hypoxic- ischaemic encephalopathy, fulfilling TOBY criteria (A, B, C).
  • ≥ 36. gest. week
  • < 6th hours of life
  • Hypothermia treatment
  • Parental consent form
  • Spontaneous breathing
  • Endotracheal intubation
  • AUC, VUC in place

Exclusion Criteria:

  • Major birth defect
  • Meconium aspiration syndrome
  • Need for combined catecholamine therapy
  • FiO2 > 40%
  • Htc < 35%
  • Acid-base status: pH < 6.8, lactate > 15mM
  • Excessive bicarbonate administration during initial stabilization (> 1mmol/kg)

Sites / Locations

  • Semmelweis University, 1st Department of Pediatrics

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

5% carbon-dioxide inhalation

Arm Description

5% carbon-dioxide will be administered through patient circuits to asphyxiated, cooled, mechanically ventilated newborns at risk for hypocapnia

Outcomes

Primary Outcome Measures

Percentage of time spent in the desired pCO2 range of 40-60 mmHg (temp. corrected) during CO2 inhalation.

Secondary Outcome Measures

Number of seizures, either detected clinically or by amplitude integrated EEG monitoring
Time until the end point of metabolic acidosis (BE > -5 mmol/L)
Time until the end point of acidosis (pH > 7.25)
Severe hypotension (mean arterial pressure less than 25 mmHg), despite full inotrope support and volume replacement.
Intracranial haemorrhage detected by MRI
Reduction in Lac/NAA ratio on magnetic resonance spectroscopy
Preserved fractional anisotropy measured on diffusion weighted MRI
Death

Full Information

First Posted
February 24, 2016
Last Updated
April 23, 2021
Sponsor
Semmelweis University
search

1. Study Identification

Unique Protocol Identification Number
NCT02700854
Brief Title
Hypoxic-Ischemic Encephalopathy Therapy Optimization in Neonates for Better Neuroprotection With Inhalative CO2
Acronym
HENRIC
Official Title
Hypoxic-Ischemic Encephalopathy Therapy Optimization for Better Neuroprotection With Inhalative CO2 in Asphyxiated, Cooled, Mechanically Ventilated Neonates at Risk for Hypocapnia
Study Type
Interventional

2. Study Status

Record Verification Date
April 2021
Overall Recruitment Status
Completed
Study Start Date
February 2016 (undefined)
Primary Completion Date
September 2019 (Actual)
Study Completion Date
November 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Semmelweis University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a Phase I, open-label, single center trial to evaluate the feasibility and safety of low concentration CO2 gas mixture (5% CO2 + 95% air) inhalation in asphyxiated, cooled, mechanically ventilated newborns at risk of hypocapnia with The hypothesis is that hypocapnia, which is driven by hyperventilation in the presence of metabolic acidosis, is deleterious to the injured brain and can be safely avoided with low concentration CO2 inhalation.
Detailed Description
Specific aims: To test the feasibility of low concentration inhalative CO2 gas mixture (5% CO2 + 95% air) administration to achieve a desired range of pCO2 of 40-60 mmHg in asphyxiated, cooled, mechanically ventilated newborns at risk of hypocapnia with moderate to severe hypoxic-ischemic encephalopathy. To test the safety of CO2 gas mixture (5% CO2 + 95% air) inhalation in asphyxiated, cooled, mechanically ventilated newborns at risk of hypocapnia with moderate to severe hypoxic-ischemic encephalopathy. Term infants (≥ 36 weeks of gestation) will have to be at risk of hypocapnia to be eligible, as defined by a temperature corrected pCO2 ≤ 40 mmHg in blood gas analysis, at any time within six hours of life. The gas mixture will be administered through patient circuits in conventional ventilators. Administered CO2 level will be closely monitored at the inhalation circuit (constant 5% = 36 mmHg). Blood gas samples will be taken hourly to ensure targeted and tolerable pCO2 levels.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypoxic-Ischaemic Encephalopathy, Perinatal Asphyxia, Hypocapnia
Keywords
Hypothermia treatment, Hypocapnia, Inhaled CO2, Neuroprotection

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Arm Title
5% carbon-dioxide inhalation
Arm Type
Experimental
Arm Description
5% carbon-dioxide will be administered through patient circuits to asphyxiated, cooled, mechanically ventilated newborns at risk for hypocapnia
Intervention Type
Other
Intervention Name(s)
5% carbon-dioxide inhalation
Other Intervention Name(s)
N-Carbogen
Intervention Description
5% CO2 (36 mmHg) and 95% air gas mixture inhalation, for a maximum of 12 hours or until metabolic acidosis recovery occurs as measured by BE > -5 mmol/L in arterial blood gas samples
Primary Outcome Measure Information:
Title
Percentage of time spent in the desired pCO2 range of 40-60 mmHg (temp. corrected) during CO2 inhalation.
Time Frame
3 days
Secondary Outcome Measure Information:
Title
Number of seizures, either detected clinically or by amplitude integrated EEG monitoring
Time Frame
Within one week
Title
Time until the end point of metabolic acidosis (BE > -5 mmol/L)
Time Frame
During CO2 inhalation (max. 12 hours)
Title
Time until the end point of acidosis (pH > 7.25)
Time Frame
During therapeutic hypothermia (max. 72 hours)
Title
Severe hypotension (mean arterial pressure less than 25 mmHg), despite full inotrope support and volume replacement.
Time Frame
During therapeutic hypothermia (max. 72 hours)
Title
Intracranial haemorrhage detected by MRI
Time Frame
Within seven days
Title
Reduction in Lac/NAA ratio on magnetic resonance spectroscopy
Time Frame
Within seven days
Title
Preserved fractional anisotropy measured on diffusion weighted MRI
Time Frame
Within seven days
Title
Death
Time Frame
Within one month

10. Eligibility

Sex
All
Maximum Age & Unit of Time
6 Hours
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: At any time within six hours of life the temperature corrected pCO2 is less than or equal to 40 mmHg after the parameters of mechanical ventilation is set according to standard protocol (SIMV+VG 5ml/kg, fr 20/min, PEEP 5 H20cm, Ti 0,35-0,45 sec). Moderate hypoxic- ischaemic encephalopathy, fulfilling TOBY criteria (A, B, C). ≥ 36. gest. week < 6th hours of life Hypothermia treatment Parental consent form Spontaneous breathing Endotracheal intubation AUC, VUC in place Exclusion Criteria: Major birth defect Meconium aspiration syndrome Need for combined catecholamine therapy FiO2 > 40% Htc < 35% Acid-base status: pH < 6.8, lactate > 15mM Excessive bicarbonate administration during initial stabilization (> 1mmol/kg)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Miklós Szabó, MD, PhD
Organizational Affiliation
Semmelweis University, 1st Department of Pediatrics
Official's Role
Study Director
Facility Information:
Facility Name
Semmelweis University, 1st Department of Pediatrics
City
Budapest
ZIP/Postal Code
1085
Country
Hungary

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
12097540
Citation
Laffey JG, Kavanagh BP. Hypocapnia. N Engl J Med. 2002 Jul 4;347(1):43-53. doi: 10.1056/NEJMra012457. No abstract available.
Results Reference
background
PubMed Identifier
21146184
Citation
Pappas A, Shankaran S, Laptook AR, Langer JC, Bara R, Ehrenkranz RA, Goldberg RN, Das A, Higgins RD, Tyson JE, Walsh MC; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Hypocarbia and adverse outcome in neonatal hypoxic-ischemic encephalopathy. J Pediatr. 2011 May;158(5):752-758.e1. doi: 10.1016/j.jpeds.2010.10.019. Epub 2010 Dec 10.
Results Reference
background
PubMed Identifier
15613575
Citation
Klinger G, Beyene J, Shah P, Perlman M. Do hyperoxaemia and hypocapnia add to the risk of brain injury after intrapartum asphyxia? Arch Dis Child Fetal Neonatal Ed. 2005 Jan;90(1):F49-52. doi: 10.1136/adc.2003.048785.
Results Reference
background
PubMed Identifier
19797281
Citation
Azzopardi DV, Strohm B, Edwards AD, Dyet L, Halliday HL, Juszczak E, Kapellou O, Levene M, Marlow N, Porter E, Thoresen M, Whitelaw A, Brocklehurst P; TOBY Study Group. Moderate hypothermia to treat perinatal asphyxial encephalopathy. N Engl J Med. 2009 Oct 1;361(14):1349-58. doi: 10.1056/NEJMoa0900854. Erratum In: N Engl J Med. 2010 Mar 18;362(11):1056.
Results Reference
background

Learn more about this trial

Hypoxic-Ischemic Encephalopathy Therapy Optimization in Neonates for Better Neuroprotection With Inhalative CO2

We'll reach out to this number within 24 hrs